Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Walid M. Awni"'
Autor:
Ahmed Salem, Walid M. Awni, Rod A. Humerickhouse, Dale Miles, Sathej Gopalakrishnan, Kevin J. Freise, William G. Wierda, Brenda Chyla, Sven Mensing, Rajeev M. Menon
Publikováno v:
Clinical pharmacology and therapeutics. 109(2)
Minimal residual disease (MRD) is an important emerging clinical end point in chronic lymphocytic leukemia (CLL). The objective of this research was to develop an integrated mechanistic model to evaluate the impact of venetoclax-rituximab combination
Autor:
Ramona C. Rodila, Walid M. Awni, Gerd-Rüdiger Burmester, Charles Locke, Sandra L. Goss, Ziyi Jin, Hartmut Kupper, Cheri E. Klein
Publikováno v:
Clinical Therapeutics. 40:309-319
Methotrexate (MTX) and adalimumab are well-recognized treatments of rheumatoid arthritis (RA), the efficacy of which may be driven by intracellular polyglutamates (PGs). The aim of this analysis was to characterize MTX PG concentrations and adalimuma
Autor:
Walid M. Awni, John J. Brennan, Chih-Wei Lin, Nael M. Mostafa, Cheri E. Klein, Dennis Andress
Publikováno v:
Clinical Therapeutics. 40:242-251
Purpose The objective of the current analyses was to characterize the pharmacokinetic properties of atrasentan and the exposure-response relationships for the efficacy end point, urinary albumin to creatinine ratio (UACR), and the treatment-emergent
Autor:
Walid M. Awni, Haoyu Wang, Akshanth R. Polepally, Rajeev M. Menon, Daniel E. Cohen, Amit Khatri, Sven Mensing, Thomas Podsadecki, Patrick J. Marroum, Balakrishna Hosmane, Mukul Minocha
Publikováno v:
The AAPS Journal. 19:1523-1535
The triple direct-acting antiviral (3-DAA) regimen (two co-formulated tablets of ombitasvir/paritaprevir/ritonavir once daily and one tablet of dasabuvir twice daily) for patients with hepatitis C virus (HCV) genotype 1 infection has been reformulate
Autor:
Walid M. Awni, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Nancy S. Shulman, Barbara DaSilva-Tillmann, Thomas Podsadecki, Rajeev M. Menon
Publikováno v:
Clinical Drug Investigation. 37:647-657
All-oral direct-acting antiviral regimens that include combinations of ombitasvir, paritaprevir, ritonavir, and dasabuvir with or without ribavirin were evaluated in hepatitis C virus-infected patients in phase II/III clinical studies. The objective
Autor:
Walid M. Awni, Amit Khatri, Thomas Podsadecki, Doerthe Eckert, Sven Mensing, Akshanth R. Polepally, Sandeep Dutta, Rajeev M. Menon, Shringi Sharma
Publikováno v:
British Journal of Clinical Pharmacology. 83:527-539
Aim To characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir-ritonavir, and dasabuvir) and adjunctive ribavirin and estimate covariate effects in a broad spectrum of subjects wit
Autor:
Aksana K. Jones, Ahmed Salem, Walid M. Awni, Sven Mensing, Kevin J. Freise, Shekman Wong, Rod A. Humerickhouse, Doerthe Eckert
Publikováno v:
Clinical Pharmacokinetics. 56:515-523
Venetoclax is a selective, potent, first-in-class B-cell lymphoma-2 inhibitor that restores apoptosis in cancer cells and has demonstrated efficacy in a variety of hematological malignancies. The objective of this research was to characterize the rel
Autor:
Walid M. Awni, Richard A. Preston, Lino Rodrigues, Thomas Marbury, Amit Khatri, Sandeep Dutta, Haoyu Wang, Rajeev M. Menon
Publikováno v:
Clinical Pharmacokinetics. 56:153-163
The direct-acting antiviral agent (DAA) combination of ombitasvir and paritaprevir (administered with ritonavir) with (3D regimen) or without (2D regimen) dasabuvir has shown very high efficacy rates in the treatment of chronic hepatitis C virus (HCV
Autor:
Walid M. Awni, Rajeev M. Menon, Thomas Podsadecki, Cheri E. Klein, Yi-Lin Chiu, Sandeep Dutta
Publikováno v:
British Journal of Clinical Pharmacology. 81:929-940
Aims Paritaprevir is a direct acting antiviral agent for use as part of a multidrug hepatitis C virus infection treatment regimen. To characterize the pharmacokinetics, safety, and tolerability of paritaprevir and determine an optimal dosing regimen
Autor:
Bifeng Ding, Sandeep Dutta, Daniel E. Cohen, Thomas Podsadecki, Jennifer R. King, Walid M. Awni, Rajeev M. Menon
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:855-861
The combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A inhibitor) coadministered with ritonavir (r), and dasabuvir (an NS5B nonnucleoside polymerase inhibitor), referred to as the 3D regimen, and the combination of ombitasvir-pari